食管疾病2026，Vol.8Issue(1)：43-49,7.DOI:10.15926/j.cnki.issn2096-7381.2026.01.008
晚期转移性食管癌一线治疗方案临床疗效的网状Meta分析
Network Meta-Analysis of Efficacy in First-Line Treatment Regimens for Advanced Metastatic Esophageal Cancer
王新帅 1赵晗宇 1陆佳 1孙庆凯 1路伟平 1韩松甫 1郭超洋1
作者信息
- 1. 河南科技大学临床医学院,河南科技大学第一附属医院,中国 洛阳,471003
- 折叠
摘要
Abstract
Objective To evaluate the efficacy of immunotherapy,radiotherapy,chemotherapy,and targeted therapy as first-line treatment regimens in patients with advanced metastatic esophageal cancer.Methods By systematically searching multiple databases such as PubMed,Embase,and Cochrane Library,information on different treatment options for advanced metastatic esophageal cancer was collected and analyzed.Cochrane risk-of-bias tool(RevMan 5.4)was employed to evaluate the quality of the included literature,and RStudio and RevMan 5.4 software were conducted to a network meta-analysis,to comprehensively evaluate the efficacy of different treatment regimens.This study used Bayesian model for frequency analysis,to complete the corresponding network meta-analysis.Results A total of 60 studies were included,involving 24 681 patients and 42 different treatment options.Among them,there are 27 randomized controlled trials involving 9 730 patients.The results showed that the combination of immunotherapy and chemotherapy ranked well,among which the"durvalumab+tremelimumab+paclitaxel+cisplatin"regimen,"camrelizumab+paclitaxel+cisplatin"regimen,and"toripalimab+paclitaxel+cisplatin"regimen all achieved good progression-free survival advantages.Conclusion In patients with advanced metastatic esophageal cancer,immunotherapy combined with chemotherapy yielded superior progression-free survival compared to both conventional chemotherapy and chemotherapy combined with targeted therapy.关键词
晚期食管癌/一线治疗/免疫治疗/化疗/放疗/靶向治疗/网状Meta分析Key words
advanced esophageal cancer/first-line treatment/immunotherapy/chemotherapy/radiotherapy/targeted therapy/network meta-analysis分类
医药卫生引用本文复制引用
王新帅,赵晗宇,陆佳,孙庆凯,路伟平,韩松甫,郭超洋..晚期转移性食管癌一线治疗方案临床疗效的网状Meta分析[J].食管疾病,2026,8(1):43-49,7.
